Copyright
©The Author(s) 2023.
World J Hepatol. Jun 27, 2023; 15(6): 841-849
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.841
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.841
Variables | Number of patients (n = 27) |
Age (± SD), yr | 72.7 (± 11.4) |
Sex | Females, 13 (48.1) |
Males, 13 (48.1) | |
Not mentioned, 1 (3.7) | |
Country of origin | Switzerland, 12 (44.4) |
Italy, 4 (14.8) | |
United States of America, 4 (14.8) | |
France, 3 (11.1) | |
Australia, 1 (3.7) | |
Canada, 1 (3.7) | |
Ireland, 1 (3.7) | |
Spain, 1 (3.7) | |
Clinical presentation | Jaundice, 15 (55.6) |
Malaise, 9 (33.3) | |
Vomiting, 9 (33.3) | |
Abdominal pain, 3 (11.1) | |
Itching, 3 (11.1) | |
Anorexia, 2 (7.4) | |
Fatigue, 2 (7.4) | |
Dyspepsia, 1 (3.7) | |
Breathlessness, 1 (3.7) | |
Pruritus, 1 (3.7) | |
Weight loss, 1 (3.7) | |
Comorbidities | Hypertension, 6 (22.2) |
Diabetes, 3 (11.1) | |
Coronary artery disease, 3 (11.1) | |
Others, 6 (22.2) | |
Other drugs causing liver injury | None, 11 (40.7) |
Statins, 4 (14.8) | |
Not mentioned, 12 (44.4) | |
DOACs implicated | Rivaroxaban, 20 (74.1) |
Apixaban, 4 (14.8) | |
Dabigatran, 3 (11.1) | |
Indications of DOACs | Atrial fibrillation, 13 (48.1) |
Pulmonary embolism, 2 (7.4) | |
Transient ischemic attack, 1 (3.7) | |
Anti-phospholipid antibody syndrome, 1 (3.7) | |
Deep vein thrombosis, 1 (3.7) | |
Major lower limb surgery, 1 (3.7) | |
Sinus node dysfunction, 1 (3.7) | |
Accidental, 1 (3.7) | |
Time to presentation after initiation of DOACs (d) | 40.6 ± 42.8 |
Need for organ support | Renal replacement therapy, 1 (3.7) |
Vasopressors, 1 (3.7) | |
Invasive mechanical ventilation, 1 (3.7) | |
Need for specific antidote | Idarucizumab, 1 (3.7) |
Days in hospital (d) | 8 ± 9.3 |
Days in ICU (d) | 7 ± 12.1 |
Outcome | Alive, 26 (96.3) |
Death, 1 (3.7) |
Parameter | Mean | Standard deviation | Range |
SGOT, at presentation (units/L) | 575.5 | 672.2 | 90-2304 |
SGPT, at presentation (units/L) | 800.2 | 1159.6 | 90-4000 |
Total bilirubin, at presentation (mg/dl) | 6.3 | 6 | 0.64-21.8 |
Direct bilirubin, at presentation (mg/dl) | 4.8 | 4.9 | 0.3-10.3 |
Alkaline phosphatase, at presentation (units/L) | 269.2 | 279.5 | 60-1039 |
- Citation: Juneja D, Nasa P, Jain R. Liver injury from direct oral anticoagulants. World J Hepatol 2023; 15(6): 841-849
- URL: https://www.wjgnet.com/1948-5182/full/v15/i6/841.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i6.841